CA Patent

CA2583716A1 — Oral dosage formulations of protease resistant polypeptides

Assigned to Nautilus Biotech SA · Expires 2008-10-18 · 18y expired

What this patent protects

Oral dosage formulations of t protease-resistant therapeutic polypeptides are provided. The dosage formulations for administration per dosage per day or per week are higher than the subcutaneous dosage. Included among the oral dosage formulations are tablets and capsules, includi…

USPTO Abstract

Oral dosage formulations of t protease-resistant therapeutic polypeptides are provided. The dosage formulations for administration per dosage per day or per week are higher than the subcutaneous dosage. Included among the oral dosage formulations are tablets and capsules, including enteric-coated forms. Methods for treatment or prevention of diseases or conditions that are treatable or preventable by the administration of such oral dosage formulations of protease-resistant polypeptides are provided.

Drugs covered by this patent

Patent Metadata

Patent number
CA2583716A1
Jurisdiction
CA
Classification
—
Expires
2008-10-18
Drug substance claim
No
Drug product claim
No
Assignee
Nautilus Biotech SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.